XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Shareholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Total CVS Health Shareholders’ Equity
Total CVS Health Shareholders’ Equity
Cumulative Effect, Period of Adoption, Adjustment
Common Shares
Treasury Shares
Common Stock and Capital Surplus
 [3]
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
 [2]
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss)
Cumulative Effect, Period of Adoption, Adjustment
 [4]
Noncontrolling Interests
Shares outstanding, beginning of year balance (in shares) at Dec. 31, 2019         1,727              
Treasury shares outstanding, beginning of year balance (in shares) at Dec. 31, 2019 [1]           (425)            
Beginning of year balance at Dec. 31, 2019 $ 64,170 $ (3) [2] $ 63,864 $ (3) [2]   $ (28,235) [1] $ 45,972 $ 45,108 $ (3) $ 1,019   $ 306
Stockholders' Equity [Roll Forward]                        
Net income 7,192   7,179         7,179       13
Other comprehensive income (loss) 395   395             395    
Stock option activity, stock awards and other (in shares)         6 0 [1]            
Stock option activity, stock awards and other 541   541       541          
ESPP issuances, net of purchase of treasury shares (in shares) [1]           2            
ESPP issuances, net of purchase of treasury shares 57   57     $ 57 [1]            
Common stock dividends (2,644)   (2,644)         (2,644)        
Other increases (decreases) in noncontrolling interests (7)                     (7)
Shares outstanding, end of year balance (in shares) at Dec. 31, 2020         1,733              
Treasury shares outstanding, end of year balance (in shares) at Dec. 31, 2020 [1]           (423)            
End of year balance at Dec. 31, 2020 69,701 $ (766) [4] 69,389 $ (766) [4]   $ (28,178) [1] 46,513 49,640   1,414 $ (766) 312
Stockholders' Equity [Roll Forward]                        
Net income 7,989   8,001         8,001       (12)
Other comprehensive income (loss) (314)   (314)             (314)    
Stock option activity, stock awards and other (in shares)         11              
Stock option activity, stock awards and other 864   864       864          
ESPP issuances, net of purchase of treasury shares (in shares) [1]           1            
ESPP issuances, net of purchase of treasury shares 5   5     $ 5 [1]            
Common stock dividends (2,644)   (2,644)         (2,644)        
Other increases (decreases) in noncontrolling interests 6                     6
Shares outstanding, end of year balance (in shares) at Dec. 31, 2021         1,744              
Treasury shares outstanding, end of year balance (in shares) at Dec. 31, 2021 [1]           (422)            
End of year balance at Dec. 31, 2021 74,841   74,535     $ (28,173) [1] 47,377 54,997   334   306
Stockholders' Equity [Roll Forward]                        
Net income 4,327   4,311         4,311       16
Other comprehensive income (loss) (1,598)   (1,598)             (1,598)    
Stock option activity, stock awards and other (in shares)         14              
Stock option activity, stock awards and other 816   816       816          
Purchase of treasury shares, net of ESPP issuances (in shares) [1]           (36)            
Purchase of treasury shares, net of ESPP issuances (3,685)   (3,685)     $ (3,685) [1]            
Common stock dividends (2,910)   (2,910)         (2,910)        
Other increases (decreases) in noncontrolling interests (22)                     (22)
Shares outstanding, end of year balance (in shares) at Dec. 31, 2022         1,758              
Treasury shares outstanding, end of year balance (in shares) at Dec. 31, 2022 [1]           (458)            
End of year balance at Dec. 31, 2022 $ 71,769   $ 71,469     $ (31,858) [1] $ 48,193 $ 56,398   $ (1,264)   $ 300
[1] Treasury shares include 1 million shares held in trust for each of the years ended December 31, 2022, 2021 and 2020. Treasury stock includes $29 million related to shares held in trust for each of the years ended December 31, 2022, 2021 and 2020. See Note 1 ‘‘Significant Accounting Policies’’ for additional information.
[2] Reflects the adoption of Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326), which resulted in a reduction to retained earnings of $3 million during the year ended December 31, 2020.
[3] Common stock and capital surplus includes the par value of common stock of $18 million as of December 31, 2022 and $17 million as of December 31, 2021 and 2020.
[4] Reflects the adoption of ASU 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts (Topic 944) during the year ended December 31, 2021. See Note 8 ‘‘Other Insurance Liabilities and Separate Accounts’’ for additional information.